Kidney transplantation in 2026 — barriers, allocation reform, and post-transplant outcomes
Twenty lectures recorded at the Perelman Center in Philadelphia map the full landscape of kidney transplantation updates for 2026 — from the hardest candidacy barriers to the latest OPTN allocation changes, living donor expansion, and post-transplant complications including cancer and cardiovascular risk. Penn Medicine faculty present case-based sessions on immunologic barriers in sensitized candidates, SPK transitions for diabetic patients, and emerging biomarkers for allograft monitoring.
-
20lectures
-
2.69 GBsize
-
12faculty
-
2026year
Inside this resource
Overcoming candidacy barriers for transplantation
Three case-based sessions confront the hardest eligibility questions: managing medical barriers in candidates with complex comorbidities, desensitizing highly sensitized patients with immunologic barriers, and navigating psychosocial barriers such as substance abuse history. Each case pairs a real clinical scenario with updated strategies for managing recurrent C3G and IgA nephropathy in the transplanted kidney.
Federal allocation policy and donor pool expansion
The course examines new federal initiatives aimed at increasing transplant access and how recent UNOS policy changes reshape the wait-list. A dedicated session addresses the IOTA organ transplant access model’s practical implications. Additional lectures cover expanding the deceased donor pool through non-traditional strategies and tailoring approaches for diabetic patients progressing from kidney-alone to simultaneous pancreas-kidney transplantation.
Post-transplant survivorship and recipient care
Long-term management receives substantial attention: cardiovascular risk reduction in transplant recipients, emerging infectious disease challenges in immunosuppressed patients, and a keynote on cancer surveillance across the transplant continuum — from candidacy evaluation through post-transplant survivorship. Updates in living kidney donation round out the clinical scope.
Biomarkers and allograft monitoring
A dedicated session guides clinicians on when and how to use emerging serum and urine markers for monitoring allograft function, detecting rejection earlier, and making immunosuppressive management decisions based on objective data rather than protocol biopsies alone.
Who this serves
- Transplant nephrologists — navigating OPTN allocation changes and optimizing post-transplant outcomes
- Transplant surgeons — expanding living and deceased donor criteria for complex candidates
- Advanced practice providers — managing immunosuppression and long-term complications in transplant recipients
Before you buy
Is this course focused on adult or pediatric transplantation?
The program is oriented toward adult kidney transplantation. Pediatric transplantation is not a primary focus of this edition.
Does the course include slides alongside the lectures?
Yes — presentation slides accompany all 20 recorded lectures as downloadable PDFs.
The chart
| Format | Video Course (20 lectures + PDFs) |
|---|---|
| Duration | 2.69 GB total |
| Year | 2026 |
| Publisher | Penn Medicine |
| Department | Nephrology |
| Delivery | Instant download after checkout · lifetime re-access |
Verified original fileInstant downloadEncrypted checkout



Robert H. –
Good variety of topics within transplantation. The SPK transition case was particularly useful for our program’s diabetic patients.
Monica L. –
As a transplant coordinator, the barrier cases were directly applicable to daily work. Already recommended it to my entire team.
James T. –
The course is adult-focused throughout. Would have appreciated at least one session on pediatric transplantation considerations.
Sarah M. –
Strong course overall. I wanted more depth on specific biomarker assays — the session covered the concept well but left me wanting protocol details.
Priya K. –
The keynote on cancer surveillance across the transplant continuum changed how I approach screening in my post-transplant patients.
David R. –
The OPTN policy session aligned perfectly with changes our transplant committee is navigating right now. Practical and current.